Six studies evaluated the predictive value of clinicopathological variables [29–31, 34–36], in which tumor location and age (both 4/6) were the most frequent, significant indicators for the prediction of MSI status, followed by carcinoembryonic antigen (3/6). This evidence concerns the gene CEACAM5 and neoplasm.